Adults who identify as African American or Black in the United States face several critical issues. First, Black adults are twice as likely to develop Alzheimer’s disease (AD) compared to their White counterparts. While Black Americans comprise only 13.4% of the population, they represent 20% of persons living with AD, with Black families providing incredible amounts of informal caregiving to affected loved ones.
The second and equally important issue is that Black Americans are severely under-represented in AD research studies, comprising less than 5% of all AD clinical trial participants. This lack of inclusion and representation means that AD advancements – from effective engagement strategies and educational materials to treatments that may decrease the risk for or prevent AD – may not work for Black adults. Furthermore, the field of aging and AD remains limited in their understanding of AD risk pathways and the safety and efficacy of investigational treatments for Black Americans and others of African ancestry.
This is the reason I am part of the AHEAD Study, the first study that aims to help prevent AD by enrolling participants as young as 55, using tailored dosing of an investigational treatment. Clinical Research professionals like me are committed to making diversity a priority in this trial. Participation by Black Americans in the AHEAD Study not only will represent the diverse makeup of this country but also leads us to a future of potential AD treatments that are safe and effective for everyone.
Be represented. Be present. Be the breakthrough. Your participation can help make a difference not just for yourself but for generations to come. Visit AHEADSTUDY.org or call us at 1-800-AHEAD-70 to learn more.
Jamilya Rahming
Marketing Team Lead
Charter Research
